ANL 29.15 Increased By ▲ 0.63 (2.21%)
ASC 16.50 Decreased By ▼ -0.18 (-1.08%)
ASL 25.15 Increased By ▲ 1.39 (5.85%)
AVN 99.18 Increased By ▲ 4.94 (5.24%)
BOP 9.51 Increased By ▲ 0.04 (0.42%)
BYCO 9.36 Decreased By ▼ -0.20 (-2.09%)
DGKC 112.10 Increased By ▲ 1.60 (1.45%)
EPCL 47.55 Increased By ▲ 0.10 (0.21%)
FCCL 21.50 Increased By ▲ 0.22 (1.03%)
FFBL 28.84 Increased By ▲ 0.87 (3.11%)
FFL 19.23 Decreased By ▼ -0.04 (-0.21%)
HASCOL 14.08 Decreased By ▼ -0.23 (-1.61%)
HUBC 86.75 Increased By ▲ 0.75 (0.87%)
HUMNL 7.25 Decreased By ▼ -0.05 (-0.68%)
JSCL 32.39 Increased By ▲ 0.92 (2.92%)
KAPCO 40.81 Increased By ▲ 0.08 (0.2%)
KEL 4.18 Increased By ▲ 0.07 (1.7%)
LOTCHEM 15.99 Decreased By ▼ -0.21 (-1.3%)
MLCF 43.90 Increased By ▲ 0.89 (2.07%)
PAEL 40.06 Increased By ▲ 0.20 (0.5%)
PIBTL 13.04 Increased By ▲ 0.13 (1.01%)
POWER 11.65 Increased By ▲ 0.25 (2.19%)
PPL 93.72 Increased By ▲ 0.42 (0.45%)
PRL 23.80 No Change ▼ 0.00 (0%)
PTC 9.37 Increased By ▲ 0.07 (0.75%)
SILK 1.22 Increased By ▲ 0.02 (1.67%)
SNGP 44.60 Increased By ▲ 0.27 (0.61%)
TRG 114.93 Increased By ▲ 6.45 (5.95%)
UNITY 33.68 Increased By ▲ 0.53 (1.6%)
WTL 1.09 Decreased By ▼ -0.03 (-2.68%)
BR100 4,903 Increased By ▲ 20.27 (0.42%)
BR30 25,401 Increased By ▲ 281.87 (1.12%)
KSE100 46,214 Increased By ▲ 126.09 (0.27%)
KSE30 19,219 Increased By ▲ 53.89 (0.28%)
Business & Finance

EU regulator starts real-time review of Moderna's COVID-19 vaccine candidate

  • The European Medicines Agency's human medicines committee has started a "rolling review" of Moderna's mRNA-1273 vaccine candidate and is evaluating the first batch of data.
  • EMA's announcement comes a week after Switzerland began a real-time review of data from Moderna's vaccine candidate.
16 Nov 2020

Europe's health regulator said on Monday it had launched a real-time review of US drugmaker Moderna Inc's experimental COVID-19 vaccine, following similar such reviews of rival vaccines from AstraZeneca and Pfizer.

The European Medicines Agency's human medicines committee has started a "rolling review" of Moderna's mRNA-1273 vaccine candidate and is evaluating the first batch of data, the regulator said.

Rolling reviews allow drug companies to submit applications for COVID-19 medicinal products before development work is concluded and prior to the availability of complete supporting documentation, aimed at speeding up any approval process.

In October, Moderna had said it would apply for real-time reviews of its vaccine in Europe.

EMA's announcement comes a week after Switzerland began a real-time review of data from Moderna's vaccine candidate.

Moderna said earlier this month that it has enough data for a first interim analysis of its late-stage COVID-19 vaccine trial.